# Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients

> **NCT03882060** · NA · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 60 (actual)

## Conditions studied

- Moyamoya Disease
- Pediatrics
- Cerebrovascular Disorders

## Interventions

- **DRUG:** erythropoietin
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT03882060
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-08
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03882060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03882060, "Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03882060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*